ArticleBiomedical chromatography : BMC2026
Mechanism of Pingchuanning in Attenuating Asthma Based on UHPLC-Q-Orbitrap HRMS and Network Pharmacology Analysis.
Article in Biomedical chromatography : BMC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
An ultrahigh-performance liquid chromatography coupled with quadrupole-Orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS) method was applied to characterize Pingchuanning (PCN) decoction and its absorbed serum constituents in asthmatic rats. A total of 107 compounds were identified in PCN, of which 36 prototypes were detected in rat serum. Network pharmacology and molecular docking of these absorbed compounds predicted ADORA2A as the core therapeutic target, with 5-O-methylvisammioside, nobiletin, sec-O-glucosylhamaudol, and 9-oxo-ODE showing binding affinity. In an ovalbumin-induced asthmatic rat model, PCN alleviated airway hyperresponsiveness and lung inflammation. Mechanistically, PCN upregulated ADORA2A, elevated cAMP and PKA phosphorylation, and suppressed NLRP3 expression. This UHPLC-Q-Orbitrap HRMS-based serum pharmacochemistry method effectively identified the bioactive components of PCN, and the integrated strategy demonstrates that PCN exerts anti-asthmatic effects through the ADORA2A/cAMP/PKA/NLRP3 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.